[Evaluation of the effectiveness of chemoradiotherapy of stage IIIA Hodgkin's disease].
A total of 106 case histories of primary patients with stage III Hodgkin's disease aged 15 and older were analyzed. The treatment consisted of 2 introductory courses of polychemotherapy after MOPP scheme followed by a radical program of radiotherapy in 2-4 weeks, resulting in 88.7% of complete remissions. The 5-year survival rate was 81.3-6.3%, a 5-year recurrence-free course was noted in 83.8-5.2%. The 5-year survival rate was significantly lower in the patients with "unfavorable" histological types (mixed cellular and lymphoid depletion). A recurrence-free course over the same period was worse in men than in women, and in the patients with 5 and more zones of involvement.
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D011379:Prognosis; D014750:Vincristine / Q000008:administration & dosage
D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D011241:Prednisone
Otsenka éffektivnosti khimioluchevogo lecheniia limfogranulematoza IIIA stadii.